Mivebresib
Cat. No.：YN270001
CAS No. ：1445993-26-9
| 产品名称: | Mivebresib |
| CAS No.: | 1445993-26-9 |
| Chemical Name: | N-[4-(2,4-difluorophenoxy)-3-(6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]-ethanesulfonamide |
| Synonyms: | 米维布塞; ABBV-075 |
| 分子量: | 459.47 |
| 分子式: | C₂₂H₁₉F₂N₃O₄S |
| SMILES: | CCS(=O)(NC1=CC=C(OC2=CC=C(F)C=C2F)C(C3=CN(C)C(C4=C3C=CN4)=O)=C1)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Mivebresib (ABBV-075) 是一种有效的，口服活性的溴结构域和末端结构域 (BET) 抑制剂。Mivebresib 与BRD4结合的Ki为 1.5 nM。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Sarthy, A., Li, L., Albpert, D.H., et al.Abstract 4718: ABBV-075, a novel BET family bromodomain inhibitor, represents a promising therapeutic agent for a broad spectrum of cancer indicationsCancer Res.76 (14 Suppl),(2016)
Faivre, E.J., Wilcox, D., Lin, X., et al.Exploitation of castration-resistant prostate cancer transcription factor dependencies by the novel BET inhibitor ABBV-075Mol. Cancer Res.15(1),35-44(2017)
Bui, M.H., Lin, X., Albert, D.H., et al.Preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategiesCancer Res.77(11),2976-2989(2017)
